İstanbul Vakıf Müzeleri

Taha Toros Arşivi, Dosya No: 114-Müzelerİstanbul Kalkınma Ajansı (TR10/14/YEN/0033) İstanbul Development Agency (TR10/14/YEN/0033

<b>Supplementary material to BEH 3854</b>

Videos 1 and 2. The interactions between each of the individuals.Video 3. A combat dance.Video 4. Waiting behavior recorded at another sandy beach.Appendix. The sttatistical code used in this study.</p

Nucleotide mutation matrix

This matrix provides the mutation state for each snake species (NA for missing data), but here the two different resistance mutations (A to G vs. A to C) at codon 120 are considered separately. Specifically, resistance mutations are encoded with 1 or 2 (2 only applies to codon 120), and the non-resistant mutation with 0. The two data columns give the two mutations in orde

Reistance mutation character state

This matrix provides the mutation state for each snake species (NA for missing data). Resistance mutations are encoded with 1, and the non-resistant mutation with 0. The two data columns give the two mutations in order

Phylogenetic tree

This is the tree we used for the analyses. This tree was originally published by Zhen and Weins (2016), and is simply included here to ensure our analyses can be recreated from the data on Dryad

Electronic Supplementary Materials from Toxin-resistant isoforms of Na⁺/K⁺-ATPase in snakes do not closely track dietary specialization on toads

Figure S1 and Table S

Plant species list and soil data

Plant species list and soil dat

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization -4

Y) or diluent when tumors became palpable. A) Treatment with ENMD-1198 led to a significant growth inhibition of xenografted hepatocellular tumors, compared to controls (*P < 0.05). B) Final tumor weights (day 19) in the ENMD-1198 treatment group were significantly lower, compared to excised tumors of the control group (*P < 0.05). Bars: mean ± SEM.<p><b>Copyright information:</b></p><p>Taken from "ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization "</p><p>http://www.biomedcentral.com/1471-2407/8/206</p><p>BMC Cancer 2008;8():206-206.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496914.</p><p></p

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization -5

Howed that vessel area was significantly reduced in ENMD-1198-treated tumors (*P < 0.01). B) ENMD-1198 significantly decreased the number of proliferating (BrdUrd-positive) tumor cells in tissue sections (*P < 0.01). For both vessel area and cell proliferation, representative images are illustrated. Results shown are the mean ± SEM. C) Western blot analysis for HIF-1α expression in HCC tumors showed a substantial reduction of HIF-1α in ENMD-1198 treated tumors.<p><b>Copyright information:</b></p><p>Taken from "ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization "</p><p>http://www.biomedcentral.com/1471-2407/8/206</p><p>BMC Cancer 2008;8():206-206.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496914.</p><p></p

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization -2

Educed cancer cell motility and blunted the response to either EGF, or HGF (*P < 0.01). B) The effects on cancer cell invasiveness were evaluated using Matrigel-coated inserts. ENMD-1198 (2.5 μM) significantly abrogated EGF- and HGF-mediated invasive properties of hepatocellular carcinoma cells, compared to controls (*P < 0.01 for all). Experiments were performed in triplicates and results were confirmed in a second cell line (HepG2). Bars: SEM.<p><b>Copyright information:</b></p><p>Taken from "ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization "</p><p>http://www.biomedcentral.com/1471-2407/8/206</p><p>BMC Cancer 2008;8():206-206.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496914.</p><p></p